Tellgen Corporation (SHE:300642)

Market Cap	2.46B -27.0%
Revenue (ttm)	393.84M +5.5%
Net Income	18.83M +18.3%
EPS	0.12 +18.5%
Shares Out	159.59M
PE Ratio	132.44
Forward PE	n/a
Dividend	0.05 (0.32%)
Ex-Dividend Date	Sep 3, 2026

Volume	9,102,400
Open	16.25
Previous Close	16.22
Day's Range	15.33 - 16.38
52-Week Range	11.04 - 22.87
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Tellgen

Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded i...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2003
• Employees: 683
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300642

Financial Performance

In 2025, Tellgen's revenue was 363.83 million, a decrease of -16.70% compared to the previous year's 436.78 million. Earnings were 3.59 million, a decrease of -89.61%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error